The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis

BACKGROUND: Tissue released blood-based biomarkers can provide insight into drug mode of action and response. To understand the changes in extracellular matrix turnover, we analyzed biomarkers associated with joint tissue turnover from a phase 3, randomized, placebo-controlled study of baricitinib i...

Descripción completa

Detalles Bibliográficos
Autores principales: Thudium, Christian S., Bay-Jensen, Anne C., Cahya, Suntara, Dow, Ernst R., Karsdal, Morten A., Koch, Alisa E., Zhang, Wenling, Benschop, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552555/
https://www.ncbi.nlm.nih.gov/pubmed/33046136
http://dx.doi.org/10.1186/s13075-020-02340-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552555/
https://www.ncbi.nlm.nih.gov/pubmed/33046136
http://dx.doi.org/10.1186/s13075-020-02340-7

Ejemplares similares